Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Galvin Gaustad & Stein LLC

Galvin Gaustad & Stein LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,890 shares of the pharmaceutical company’s stock after purchasing an additional 1,529 shares during the quarter. Galvin Gaustad & Stein LLC’s holdings in Vertex Pharmaceuticals were worth $10,191,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in VRTX. Commerzbank Aktiengesellschaft FI grew its stake in Vertex Pharmaceuticals by 453.1% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 9,850 shares of the pharmaceutical company’s stock valued at $4,386,000 after acquiring an additional 8,069 shares during the period. Callan Family Office LLC grew its stake in Vertex Pharmaceuticals by 203.0% in the 2nd quarter. Callan Family Office LLC now owns 16,715 shares of the pharmaceutical company’s stock valued at $7,441,000 after acquiring an additional 11,198 shares during the period. TFR Capital LLC. grew its stake in Vertex Pharmaceuticals by 4.1% in the 2nd quarter. TFR Capital LLC. now owns 4,950 shares of the pharmaceutical company’s stock valued at $2,204,000 after acquiring an additional 194 shares during the period. Boomfish Wealth Group LLC grew its stake in Vertex Pharmaceuticals by 3.8% in the 2nd quarter. Boomfish Wealth Group LLC now owns 5,243 shares of the pharmaceutical company’s stock valued at $2,334,000 after acquiring an additional 192 shares during the period. Finally, US Bancorp DE grew its stake in Vertex Pharmaceuticals by 4.1% in the 2nd quarter. US Bancorp DE now owns 33,583 shares of the pharmaceutical company’s stock valued at $14,951,000 after acquiring an additional 1,324 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on VRTX shares. Citigroup lifted their price target on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Scotiabank dropped their price target on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. Stifel Nicolaus dropped their price target on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a research note on Tuesday, August 5th. Cantor Fitzgerald dropped their price target on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Finally, Royal Bank Of Canada decreased their price objective on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $494.43.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $414.86 on Friday. The stock’s fifty day moving average is $394.99 and its two-hundred day moving average is $440.30. The firm has a market capitalization of $106.37 billion, a P/E ratio of 29.65 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the previous year, the firm earned ($12.83) EPS. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.